AstraZeneca COPD drug delivers 2 phase 3 wins

AstraZeneca’s tozorakimab is the first biologic to demonstrate statistically significant efficacy in reducing moderate and severe COPD exacerbations in a broad population of patients who continued to experience exacerbations while receiving inhaled standard-of-care therapy. Tozorakimab reduced moderate and severe COPD exacerbations among former smokers by 29% in Oberon and 34% in Titania, according to a […] The post AstraZeneca COPD drug delivers 2 phase 3 wins appeared first on Beck...